Ryan Specialty Group (RYAN) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
17 Mar, 2026Voting matters and shareholder proposals
Election of five director nominees: David P. Bolger, Michael G. Bungert, Francesca Comelli, Nicholas D. Cortezi, and Anthony J. Kuczinski, with board recommending a vote for each.
Ratification of Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, recommended for approval.
Advisory vote to approve compensation of named executive officers (say-on-pay), recommended for approval.
Board of directors and corporate governance
Five director nominees are presented for election at the annual meeting.
Executive compensation and say-on-pay
Advisory vote on executive compensation is included as a proposal, with board recommending approval.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Ryan Specialty Group
- Record revenue, expanded shareholder rights, and a focus on performance-based leadership mark 2025.RYAN
Proxy Filing17 Mar 2026 - 2025 revenue up 21.3% to $3.1B, with 10.1% organic growth and $300M buyback authorized.RYAN
Q4 202527 Feb 2026 - Q2 revenue up 23% to $855.2M, net income up 5.6%, guidance lowered amid property headwinds.RYAN
Q2 202512 Feb 2026 - Q3 revenue up 25% and net income up 118.6%, with strong organic growth and margin pressures from investments.RYAN
Q3 202512 Feb 2026 - Double-digit growth and E&S market leadership driven by complexity, scale, and innovation.RYAN
Investor presentation12 Feb 2026 - Revenue up 18.8%, net income up 40.8%, with margin and guidance both raised.RYAN
Q2 20242 Feb 2026 - Double-digit growth and margin expansion are fueled by E&S specialization, M&A, and innovation.RYAN
The 44th Annual William Blair Growth Stock Conference1 Feb 2026 - Strategic acquisitions, leadership continuity, and E&S market growth drive future expansion.RYAN
2024 KBW Insurance Conference22 Jan 2026 - Q3 revenue up 20.5%, net income up 82.4%, and adjusted EBITDA up 29.4% year-over-year.RYAN
Q3 202417 Jan 2026